Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Pharmaceutical Executive October 1, 2010	Nobel Laureate Elie Wiesel Exclusive Interview Ethical behavior can be a bridge-builder in an era where Big Pharma needs to find new partners. Is it up to the challenge?
Pharmaceutical Executive July 1, 2012 William Looney	Less, But Better Pharm Exec's 2012 roster of Emerging Leaders is not only a way to recognize a few individuals who've made a difference in their organizations. It also serves as a barometer to track larger changes in the workplace.
Pharmaceutical Executive August 1, 2014 William Looney	A Window on the Industry: The Emerging Pharma Leaders 2014 Pharm Exec's 2014 roster of emerging pharma leaders serves as a window on work in an industry that relies on human capital as the coinage of success.
Pharmaceutical Executive June 1, 2011	Emerging Pharma Leaders 2011 Meet 2011's Emerging Pharma Leaders. Can these 30 trendsetters build competitive scale from scarcity?
Pharmaceutical Executive January 1, 2011	The San Diego Story San DIego works as a locus for risky investments in the big ideas that lead to biotech breakthroughs
Pharmaceutical Executive January 1, 2013 William Looney	The Long Swim -- Upstream As we near the midway point in the "tween" decade, there is good fortune in store for those in the pharmaceutical industry with the perspective that comes with the long view.
Pharmaceutical Executive December 1, 2010 William Looney	In Through the Out Door The end of anther year is an appropriate time to highlight the march of time and the transitions that accompany it in Europe and in China.
Pharmaceutical Executive January 1, 2013 Clark Herman	Who Lost Syria? Thankfully, the civil war is not a public relations issue for Big Pharma, but the long-term business implications for the Middle East region are cagey.
Pharmaceutical Executive August 1, 2014 William Looney	A Mission to Transform Mid-career students at Brown University's new Executive Masters in Healthcare Leadership program are challenging the status quo with workplace projects focused on one thing: removing the organizational silos.
Pharmaceutical Executive April 1, 2014 William Looney	The Trials of Commerce Four commercial line executives serve as our jury of peers on what's in store for the future of pharma, and discuss the changing criteria for market success, from drugs to consumer products to vaccines.
Pharmaceutical Executive January 1, 2012 William Looney	The Well of Engagement We sometimes forget that the business of healthcare is also the source of a huge opportunity: improving the human condition.
Pharmaceutical Executive January 1, 2012 William Looney	Pharma 2012: Hard Times Before the Harvest 2012 will be a transition year for pharma, one of the most important in its history. The challenge is that many new treatments may not complete the move from 'bench to bedside' in time to plug the yawning revenue gap.
Pharmaceutical Executive December 1, 2010	The Sum of All His Parts: Career Reflections of Europe's Chief Drug Regulator The European Medicines Agency is a unique institution, pursuing a mandate shared with a complex web of national and regional groups, each able to place a distinctive imprint around the delicate task of certifying the safety and efficacy of new drugs.
Pharmaceutical Executive April 1, 2011 William Looney	Platforms for Peerless Performance A true performance culture has to focus on the mundane as much as the sublime.
Pharmaceutical Executive April 1, 2011	The Big Business of Boosting Performance Dutch-based DSM N.V. is seeking innovative ways to partner through bolstering manufacturing.
Pharmaceutical Executive July 1, 2012 William Looney	The Learning Curve In a wake up call to this year's Emerging Leaders a group of St. Joseph's Business School Health Management alumni say time has no limit on surprises; change for pharma is here and it's good.
Pharmaceutical Executive September 1, 2013 William Looney	High Noon For Hot Markets Fading growth, overstretched governments, and a global governance backlash against pharma business are turning up the heat on the performance of emerging country markets.
Pharmaceutical Executive July 1, 2012	Emerging Pharma Leaders 2012 Meet 2012's Emerging Pharma Leaders. Can these 15 global trend setters set the mark on their time in history by doing better with less while tapping new opportunities from science and technology to build competitive scale?
Pharmaceutical Executive September 1, 2010	Looking Beyond the Patent Cliff Pfizer's VP and Assistant General Counsel for Global Patents and Policy, Roy Waldron, discusses its collaborative strategy to refresh the face of IP.
Pharmaceutical Executive December 1, 2010 William Looney	Is Euroland Following the US Disclosure Lead? Cegedim Relationship Management survey documents whether European industry is ready for the challenge of new compliance and disclosure risks on promotional spending.
Pharmaceutical Executive February 4, 2011 William Looney	The Night Stalkers: Keeping CEOs Awake in 2011 The consensus is that 2011 will be a bad year for Big Pharma. Let's inventory a few of the 'night stalkers -- issues that are likely to keep members of the C-suite awake beyond a sensible 'lights out' time.
Pharmaceutical Executive September 1, 2010	Explaining the Drug Drought Industry needs to engage in a broader public debate on ways to rekindle the innovative engine in new drug discovery and development.
Pharmaceutical Executive January 1, 2012	Compliance: Getting Those Ducks in a Row Pharma must coordinate the efforts of medical, legal, HR, global partners and many other players in the regulatory compliance space to keep itself afloat in choppy seas.
Pharmaceutical Executive August 1, 2013 William Looney	One Company -- One Moment The trade media is ablaze with lurid accounts of bribery, tax fraud, and other illicit promotional activities in China -- ironically, the country touted as guarantor of our industry's future.
Pharmaceutical Executive January 21, 2014 William Looney	For Russia -- Tough Love Pharm Exec begins its 34th year with a feature on Russia's ambitious plans to build a homegrown biopharma business. Back in 1980, the biotech industry did not exist.
Pharmaceutical Executive November 1, 2008	No Ordinary Joe It's been a year since consumer marketing master Joe Jimenez took over the top spot at Novartis Pharma. How's he faring?
Pharmaceutical Executive July 1, 2013 Looney et al.	Pharm Exec's 2013 Emerging Pharma Leaders Meet the Emerging Pharma Leaders of 2013. These 15 trend setters represent the future of an industry that knows it must change: the question is how, and to what?
Pharmaceutical Executive March 1, 2014 William Looney	The Community Ethic Regardless of how you define it, partnership is also an institutional necessity as big Pharma adjusts to disruptive changes in the way health services are financed and delivered.
Pharmaceutical Executive July 1, 2013 Richie Etwaru	Innovation Calls Across the C-suite: Lessons From Wall Street The lifeblood of the life sciences industry is continuous innovation; it is not a business that can survive by standing still.
Pharmaceutical Executive September 1, 2011 Richard Barker	Innovating Around Innovation The former Director General of ABPI, proposes a new agenda on how to restore public confidence in the value behind science.
Pharmaceutical Executive October 1, 2008 Patrick Clinton	Future Shock A vision of pharma's next business model is starting to emerge. But how do we get from here to there?
Pharmaceutical Executive April 1, 2006 Ron Feemster	Thought Leader: Q&A with Joel A. Tune Pharma still enlists contract manufacturers as safety valves, but today's drug developers have also begun to outsource the production of increasingly complicated compounds while they are still in clinical trials.
Fast Company Buzz Aldrin	Buzz Aldrin On Tinkering With The Bounds Of What's Possible What does an astronaut know about facilitating business and fostering innovation?
Pharmaceutical Executive May 1, 2011 William Looney	Keeping Your Place on the Nifty 50 What do the Pharm Exec 50 numbers tell us? The dominant theme seems to be one of gradual restructuring toward a post-patent-cliff era.
Pharmaceutical Executive May 1, 2005	Thought Leaders: Playing Field in Biotech/Pharma Partnerships Levels As infrastructure and business savvy within biotechs become increasingly sophisticated, the sector's relationship with pharma is taking on a new shape. An interview with industry veteran Lisa Drakeman on how to integrate cultures and processes and where pharma is falling short.
Pharmaceutical Executive June 1, 2011	2011 Dealmakers Outlook With Yankee stadium as the backdrop, Pharm Exec convened on March 29 its annual panel of eight business development experts to crack the bat on best practice in licensing for the year ahead.
Bio-IT World January 21, 2005 Jim Golden	Top 10 Trends for 2005 Pharmacovigilance, compliance, outsourcing, and the CIO's role will be big this year.
Pharmaceutical Executive May 1, 2005 Joanna Breitstein	Eisai's New Leadership Japanese pharmaceutical Eisai's US president and COO Lonnel Coats, and chairman and CEO Hajime Shimizu, talk about their first year on the job.
Pharmaceutical Executive March 1, 2014 William Looney	The Call to Community: A Conversation with Dr. David Nash Population health is the foundation for much of what is truly new in US health reform. For big Pharma, it represents yet another escalation in expectations.
Pharmaceutical Executive September 1, 2011 William Looney	Get Back in the Box! Despite the gloom, most forecasts show the US will stay atop the industry in profits for at least the next generation of products.
Pharmaceutical Executive August 1, 2011 William Looney	Innovation at Pfizer A Q and A with Kristin Peck, the drug maker's Executive Vice President, Worldwide Business Development and Innovation.
Pharmaceutical Executive January 21, 2014 William Looney	Russia's Bet on Biopharma Can innovation trump ideology? Russia faces a stark choice in betting on the visible hand of government in promoting a "world class" biopharmaceutical sector
Pharmaceutical Executive April 1, 2014 William Looney	Dividing Lines Three examples this month show that, in our industry, there are always two sides at least to every question when we discuss who is your customer, health articles on Wikipedia, and diversity in the C-suite.
Pharmaceutical Executive April 1, 2011	How US Health Reform Is Hitting Canada Canada's Russell Williams, of Rx&D, talks about the impact of US health reform on his role as chief spokesman for the country's R&D industry.
Pharmaceutical Executive April 1, 2007 Walter Armstrong	Make It New To fix pharma's business model, nothing less than big, bold, and risky fits the bill. Two radical new visions focus on getting back to the roots of innovation -- and letting a thousand flowers bloom.
Pharmaceutical Executive October 1, 2014 William Looney	Youthquake You may not realize it, but the demographic "youth skew" in America is shaping healthcare and that's a good thing.
Pharmaceutical Executive June 1, 2012	2012 Dealmakers Outlook With Yankee Stadium as the backdrop, Pharm Exec convened on its annual panel of heavy hitters in business development to crack the bat on best practices in licensing and for the year ahead.
Pharmaceutical Executive January 1, 2011 William Looney	The Night Stalkers "Tops in Fraud" is a ruinous moniker for pharma -- a business so dependent on basic issues of trust, integrity, and quality.
Managed Care February 2002 Ira Studin	Reframing the Pharmaceutical Manufacturer/Health Plan Relationship in Managed Care It is suggested that health plans address "total cost-of-care savings" in their budget process, and the pharmaceutical manufacturers establish a "consultative service function" in their managed care divisions...
Pharmaceutical Executive May 1, 2012 William Looney	Seeding Beyond the Base The pharmaceutical industry's reputation as a growth industry no one wants to pay for is more secure than ever.